according to expert consensus, the combination of idarucizumab and IVT is suggested f or patients with acute ischemic stroke of administration of thrombolysis after prior neutralization of the effect of dabigatran with the antidote PRAXBIND is possible (IVT is an emergency procedure).In life-threatening or uncontrolled bleeding. Clinicians should verify availability with their relevant Drug and Therapeutics Committee and Pharmacy Department. IVT may be considered in patients with normal TT or TT 6h after the last dose of the drug indicates the absence of anticoagulant activity Praxbind (idarucizumab) is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: For emergency surgery/urgent procedures. IDARUCIZUMAB may not be available in all facilities.normal aPTT alone is not sufficient it does not completely rule out an elevated TT.intravenous thrombolysis (IVT) in patients with acute ischemic stroke is possible with dabigatran therapy if aPTT + TT, ECT, or HEMOCLOT values do not exceed the upper limits of normal (AHA/ASA 2013 III/C).

Idarucizumab indication